Latest & greatest articles for colorectal cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on colorectal cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on colorectal cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for colorectal cancer

1. Colorectal cancer

Colorectal cancer Colorectal cancer NICE guideline Published: 29 January 2020 www.nice.org.uk/guidance/ng151 © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Your responsibility Your responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals and practitioners are expected to take (...) an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Colorectal cancer (NG151) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 45Contents Contents Overview 5 Who is it for? 5 Recommendations 6 1.1 Prevention of colorectal cancer in people with Lynch syndrome 6 1.2 Information for people with colorectal cancer 6 1.3

2020 National Institute for Health and Clinical Excellence - Clinical Guidelines

2. Cancer Screening: Interventions Engaging Community Health Workers – Colorectal Cancer

Cancer Screening: Interventions Engaging Community Health Workers – Colorectal Cancer Colorectal Cancer: Community Health Workers | The Community Guide Welcome to The Community Guide! Let us know what you think of the website by completing this . Open Navigation or Search form Search Search The Community Guide You are here » Systematic Review Topic Recommended (strong evidence) April 2019 Audience Adults Low-income Population Setting Clinical/Health Systems Community Home Strategy Health (...) Education Screening Cancer Screening: Interventions Engaging Community Health Workers – Colorectal Cancer Tabs Snapshot Summary of CPSTF Finding The interventions that engage community health workers to increase screening for colorectal cancer by colonoscopy or fecal occult blood test [FOBT]. Evidence shows these interventions increase colorectal cancer screening rates when community health workers deliver them independently or as part of an implementation team. Interventions that engage community

2020 Community Preventive Services Task Force

3. Real-world effectiveness and safety of drug treatments for metastatic colorectal cancer: a protocol for systematic review and network meta-analysis

Real-world effectiveness and safety of drug treatments for metastatic colorectal cancer: a protocol for systematic review and network meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2020 PROSPERO

4. FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109)

FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109) FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109) - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go (...) your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation J Clin Oncol Actions , 37 (35), 3401-3411 2019 Dec 10 FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109

2020 EvidenceUpdates

5. British Society of Gastroenterology/Association of Coloproctology of Great Britain and Ireland/Public Health England post-polypectomy and post-colorectal cancer resection surveillance guidelines Full Text available with Trip Pro

British Society of Gastroenterology/Association of Coloproctology of Great Britain and Ireland/Public Health England post-polypectomy and post-colorectal cancer resection surveillance guidelines British Society of Gastroenterology/Association of Coloproctology of Great Britain and Ireland/Public Health England Post-Polypectomy and Post-Colorectal Cancer Resection Surveillance Guidelines - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set (...) Post-Polypectomy and Post-Colorectal Cancer Resection Surveillance Guidelines , , , , , , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Gastroenterology, University Hospital of North Tees, Stockton-on-Tees, UK matt.rutter@nth.nhs.uk. 2 Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK. 3 Translational Gastroenterology Unit, John Radcliffe Hospital, Oxford, UK. 4 Gastroenterology, South Tyneside NHS Foundation Trust, South Shields, UK. 5 Western

2020 EvidenceUpdates

6. Endoscopic management of Lynch syndrome and of familial risk of colorectal cancer: European Society of Gastrointestinal Endoscopy (ESGE) Guideline

Endoscopic management of Lynch syndrome and of familial risk of colorectal cancer: European Society of Gastrointestinal Endoscopy (ESGE) Guideline EndoscopicmanagementofLynchsyndromeandof familialriskof colorectalcancer:EuropeanSocietyofGastrointestinalEndoscopy (ESGE) Guideline Authors MoniqueE. vanLeerdam 1,2 ,VictorineH.Roos 3 ,JeaninE.vanHooft 3 ,FrancescBalaguer 4,5 ,EvelienDekker 3 ,MichalF. Kaminski 6,7,8 ,AndrewLatchford 9,10 ,HelmutNeumann 11 ,LuigiRicciardiello 12 ,MariaRupinska 6,7 (...) that practice monitoring of compliance and endoscopic performance measures. Strong recommendation, low quality evidence, level of agreement 100%. Appendices 1s,2s Online content viewableat: https://doi.org/10.1055/a-1016-4977 Guideline 1082 van Leerdam Monique E. et al. Endoscopic managementof Lynch syndromeand of familial riskofcolorectal cancer… Endoscopy 2019; 51: 1082–1093 Elektronischer Sonderdruck zur persönlichen Verwendung 1Introduction Colorectal cancer (CRC) is the fourth most incident cancer

2020 European Society of Gastrointestinal Endoscopy

7. A systematic review of the effect of rurality on breast, colorectal and cervical cancer screening uptake in developed countries

A systematic review of the effect of rurality on breast, colorectal and cervical cancer screening uptake in developed countries Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2020 PROSPERO

8. Colorectal Cancer

Colorectal Cancer 1.1 Editors © German Guideline Program in Oncology | Evidenced-based Guideline for Colorectal Cancer | Version 2.1 | Januar 2019 1 Evidenced-based Guideline for Colorectal Cancer Version 2.1 – Januar 2019 AWMF-Registration Number: 021/007OL 1.1 Editors © German Guideline Program in Oncology | Evidenced-based Guideline for Colorectal Cancer | Version 2.1 | Januar 2019 2 Table of Contents 1. Information on this Guideline 11 1.1. Editors 11 1.2. Leading Professional Society 11 (...) Program in Oncology | Evidenced-based Guideline for Colorectal Cancer | Version 2.1 | Januar 2019 3 3.1. Lifestyle Habits 29 3.2. Diet Recommendations 30 3.3. Micronutrients 34 3.4. Drugs 35 4. Screening Asymptomatic Population 38 4.1. Screening - Age 38 4.2. Methods of Colorectal Screening/Prevention 38 4.2.1. Endoscopic Methods 39 4.2.1.1. Colonoscopy 39 4.2.1.2. Sigmoidoscopy 40 4.2.1.3. Capsule-Colonoscopy 41 4.2.2. Stool Tests 42 4.2.2.1. Fecal Occult Blood Test (FOBT) 42 4.2.2.2. Genetic

2019 German Guideline Program in Oncology

9. Endoscopic management of Lynch syndrome and of familial risk of colorectal cancer

Endoscopic management of Lynch syndrome and of familial risk of colorectal cancer Endoscopic management of Lynch syndrome and of familial risk of colorectal cancer: European Society of Gastrointestinal Endoscopy (ESGE) Guideline – European Society of Gastrointestinal Endoscopy (ESGE) +49-89-9077936-11 Menu DOI https://doi.org/10.1055/a-1016-4977 | Endoscopy 2019; 51:1082–1093 Published online: 9.10.2019 © Georg Thieme Verlag KG Stuttgart · New York Explore the ESGE website Menu Contact us +49

2019 European Society of Gastrointestinal Endoscopy

10. Endoscopic surveillance after surgical or endoscopic resection for colorectal cancer

Endoscopic surveillance after surgical or endoscopic resection for colorectal cancer Endoscopic surveillance after surgical or endoscopic resection for colorectal cancer: European Society of Gastrointestinal Endoscopy (ESGE) and European Society of Digestive Oncology (ESDO) Guideline – European Society of Gastrointestinal Endoscopy (ESGE) +49-89-9077936-11 Menu DOI https://doi.org/10.1055/a-0831-2522 Endoscopy 2019; 51: 266–277 © Georg Thieme Verlag KG Stuttgart· New York Explore the ESGE

2019 European Society of Gastrointestinal Endoscopy

11. Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy Full Text available with Trip Pro

Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a clinical practice guideline | The BMJ Intended for healthcare professionals Username * Password * Edition: Search form Search Search Colorectal cancer... Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a clinical practice guideline (Published 02 October 2019) Cite (...) this as: BMJ 2019;367:l5515 Visual summary of recommendation No screening FIT Every year FIT Every two years Sigmoidoscopy Single Colonoscopy Single Favours no screening Favours screening We suggest no screening Interventions compared Recommendations Screening options Population We suggest using a tool such as the QCancer® calculator to estimate the risk of colorectal cancer for each person in the next 15 years. This calculates risk, based on: Understanding a person’s risk of cancer can help to determine

2019 BMJ Rapid Recommendations

12. Bevacizumab (Zirabev) - colorectal cancer, non-small cell lung cancer, peritoneal cancer, glioblastoma

Bevacizumab (Zirabev) - colorectal cancer, non-small cell lung cancer, peritoneal cancer, glioblastoma Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity

2019 Health Canada - Drug and Health Product Register

13. Colorectal cancer screening with faecal testing, sigmoidoscopy or colonoscopy: a systematic review and network meta-analysis Full Text available with Trip Pro

Colorectal cancer screening with faecal testing, sigmoidoscopy or colonoscopy: a systematic review and network meta-analysis Evaluate effectiveness, harms and burdens of faecal blood testing, sigmoidoscopy and colonoscopy screening for colorectal cancer over 15 years.We performed an update of a Cochrane systematic review, and performed network meta-analysis comparing randomised trials evaluating colorectal cancer screening with guaiac faecal occult blood test (gFOBT) (annual, biennial), faecal (...) immunochemical test (FIT) (annual, biennial), sigmoidoscopy (once-only) or colonoscopy (once-only) in a healthy population, aged 50-79 years. We conducted subgroup analysis on sex. Follow-up >5 years was required for analysis of colorectal cancer incidence and mortality.12 randomised trials proved eligible. Compared with no-screening, we found high certainty evidence for sigmoidoscopy screening slightly reducing colorectal cancer incidence (relative risk (RR) 0.76; 95% confidence interval (CI 0.70 to 0.83

2019 EvidenceUpdates

14. Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a microsimulation modelling study. Full Text available with Trip Pro

Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a microsimulation modelling study. To estimate benefits and harms of different colorectal cancer screening strategies, stratified by (baseline) 15-year colorectal cancer risk.Microsimulation modelling study using MIcrosimulation SCreening ANalysis-Colon (MISCAN-Colon).A parallel guideline committee (BMJ Rapid Recommendations) defined the time frame and screening interventions, including selection (...) of outcome measures.Norwegian men and women aged 50-79 years with varying 15-year colorectal cancer risk (1-7%).Four screening strategies were compared with no screening: biennial or annual faecal immunochemical test (FIT) or single sigmoidoscopy or colonoscopy at 100% adherence.Colorectal cancer mortality and incidence, burdens, and harms over 15 years of follow-up. The certainty of the evidence was assessed using the GRADE approach.Over 15 years of follow-up, screening individuals aged 50-79 at 3% risk

2019 BMJ

15. Mvasi for Metastatic Colorectal Cancer / Non-Small Cell Lung Cancer Biosimilar – Details

Mvasi for Metastatic Colorectal Cancer / Non-Small Cell Lung Cancer Biosimilar – Details Mvasi for Metastatic Colorectal Cancer / Non-Small Cell Lung Cancer Biosimilar – Details | CADTH.ca Find the information you need Mvasi for Metastatic Colorectal Cancer / Non-Small Cell Lung Cancer Biosimilar – Details Mvasi for Metastatic Colorectal Cancer / Non-Small Cell Lung Cancer Biosimilar – Details Project Number pCODR 10158 Brand Name Mvasi Generic Name Bevacizumab Strength 100 mg and 400 mg Tumour (...) Type Gastrointestinal / Lung Indication Metastatic Colorectal Cancer / Non-Small Cell Lung Cancer Biosimilar Funding Request For first-line treatment of patients with metastatic carcinoma of the colon or rectum, in combination with fluoropyrimidine based chemotherapy / For treatment of patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer, in combination with carboplatin/paclitaxel chemotherapy regimen Review Status Final Biosimilar Dossier Issued Pre

2019 CADTH - Pan Canadian Oncology Drug Review

16. Trifluridine and Tipiracil (Lonsurf) for Metastatic Colorectal Cancer Resubmission – Details

Trifluridine and Tipiracil (Lonsurf) for Metastatic Colorectal Cancer Resubmission – Details Trifluridine and Tipiracil (Lonsurf) for Metastatic Colorectal Cancer Resubmission – Details | CADTH.ca Find the information you need Trifluridine and Tipiracil (Lonsurf) for Metastatic Colorectal Cancer Resubmission – Details Trifluridine and Tipiracil (Lonsurf) for Metastatic Colorectal Cancer Resubmission – Details Project Number pCODR 10173 Brand Name Lonsurf Generic Name Trifluridine and Tipiracil (...) Strength 15 mg & 20 mg Tumour Type Gastrointestinal Indication Metastatic Colorectal Cancer Funding Request Treatment of adult patients with mCRC who have been previously treated with, or are not candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF biological agents, and, if RAS wild-type, anti-EGFR agents Review Status Notification to Implement Issued Pre Noc Submission No NOC Date January 25, 2018 Manufacturer Taiho Pharma Canada

2019 CADTH - Pan Canadian Oncology Drug Review

17. Guidelines for the management of hereditary colorectal cancer

Guidelines for the management of hereditary colorectal cancer Guidelines for the management of hereditary colorectal cancer from the British Society of Gastroenterology (BSG)/ Association of Coloproctologists of Great Britain and Ireland (ACPGBI)/ United Kingdom Cancer Genetics Group (UKCGG) Authors *Kevin J Monahan, BSG, Consultant Gastroenterologist, Family Cancer Clinic, St Marks Hospital, Harrow, London; Department of Surgery and Cancer, Imperial College, London. Malcolm Dunlop, ACPGBI (...) , UKCGG, Consultant Clinical Geneticist, Guy's and St Thomas' NHS Foundation Trust, London. Ian Tomlinson, UKCGG, Director of Institute of Cancer and Genomic Sciences, University of Birmingham Huw Thomas, BSG, Professor of Medicine and Consultant Gastroenterologist, Family Cancer Clinic, St Marks Hospital, Harrow, London; Department of Surgery and Cancer, Imperial College, London. James Hill, ACPGBI, Clinical Professor of Colorectal Surgery, Manchester Royal Infirmary and Manchester Academic Health

2019 British Society of Gastroenterology

18. Occult Blood Detection Testing for Non-Colorectal Cancer Related Medical Conditions: Clinical Effectiveness

Occult Blood Detection Testing for Non-Colorectal Cancer Related Medical Conditions: Clinical Effectiveness Occult Blood Detection Testing for Non-Colorectal Cancer Related Medical Conditions: Clinical Effectiveness | CADTH.ca Find the information you need Occult Blood Detection Testing for Non-Colorectal Cancer Related Medical Conditions: Clinical Effectiveness Occult Blood Detection Testing for Non-Colorectal Cancer Related Medical Conditions: Clinical Effectiveness Last updated: April 15 (...) , 2019 Project Number: RA1026-000 Product Line: Research Type: Devices and Systems Report Type: Reference List Result type: Report Question What is the clinical effectiveness of the fecal immunochemical test in detecting medical conditions other than colorectal cancer where occult blood detection is needed? What is the clinical effectiveness of the guaiac fecal blood occult test in detecting medical conditions other than colorectal cancer where occult blood detection is needed? Key Message

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

19. Colorectal Cancer Screening Evidence Brief

Colorectal Cancer Screening Evidence Brief 1 Age to Initiate Colorectal Cancer Screening in Average Risk Individuals: Evidence Brief, June 2019 Key Points • Colorectal cancer incidence and mortality are increasing in individuals under age 50. • Simulation models suggest there may be benefit to screening average risk patients beginning at age 45, but it is unclear if this benefit outweighs the risks of screening • Patients age 45-49 who express interest in screening should be engaged in shared (...) -decision making to discuss the risks and benefits • It is strongly recommended that all average risk patients 50 years and older should be screened for colon cancer • Extra vigilance for symptoms and risk factors of colon cancer (including family history in people aged 45-49) is advised given increasing colorectal cancer rates in this group. Definition of Average Risk This guidance applies to individuals at average risk for colorectal cancer. Patients not considered average risk include those

2019 Institute for Clinical Systems Improvement

20. Post-polypectomy and post-colorectal cancer resection surveillance guidelines

Post-polypectomy and post-colorectal cancer resection surveillance guidelines 1 | P a g e BSG/ACPGBI/PHE Post-polypectomy and post-colorectal cancer resection surveillance guidelines Title page Lead author & corresponding author: Professor Matthew D. Rutter Professor of Gastroenterology (1) University Hospital of North Tees, Stockton-on-Tees, TS19 8PE, UK (address for correspondence) (2) Faculty of Medical Sciences, Newcastle University, Newcastle-upon-Tyne, UK Matt.rutter@nth.nhs.uk +44 (0 (...) words 3 | P a g e Abstract These consensus guidelines were jointly commissioned by the British Society of Gastroenterology, the Association of Coloproctology of Great Britain and Ireland and Public Health England. They provide an evidence-based framework for the use of surveillance colonoscopy and non-colonoscopic colorectal imaging in people aged 18 and over. They are the first guidelines that take into account the introduction of national bowel cancer screening. For the first time, they also

2019 British Society of Gastroenterology